Muna Therapeutics’ Alzheimer’s drug targets key immune pathway identified in new study

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Muna Therapeutics announced on 4 June 2026 that a study led by collaborators across Europe was published in Nature Medicine, reporting that microglial state transitions play a central role in Alzheimer’s disease.

The research used Muna’s MiND-MAP platform together with spatial transcriptomics and single-cell methods to map brain environments and to show that disease progression depends not only on amyloid and tau accumulation but on how microglia respond to those pathologies.

A key finding was the identification of a tipping point where microglia shift from an early, potentially protective inflammatory state to a later phenotype associated with tau pathology and neurodegeneration.

The early protective response was found to be enriched for TREM2-related signaling, a pathway genetically linked to Alzheimer’s risk and the primary target of Muna’s Phase 1 clinical candidate MNA-001, which the company claims is a potent, selective, orally administered small molecule.

The study also observed that cognitively intact individuals, including centenarians, may avoid harmful microglial transitions or uncouple microglial activation from tau accumulation, a result the company says supports its strategy to enhance innate neuroprotection as it advances MNA-001 through Phase 1 testing.

Source: https://www.prnewswire.com/news-releases/muna-therapeutics-announces-nature-medicine-publication-validating-microglial-state-transitions-as-key-drivers-of-alzheimers-302790718.html

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Novartis exits a BioArctic deal worth up to $802m

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE